New England Biolabs published a study introducing Mucilaginibacter paludis Argonaute (Mpa Ago) as a programmable RNA restriction enzyme that cleaves messenger RNAs at precise, user-defined sites without CRISPR-Cas sequence constraints.

Established in the mid 1970's, New England Biolabs, Inc. (NEB) is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including the development of molecular diagnostics, as well as nucleic acid vaccines. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and subsidiaries located in Australia, Canada, China, France, Germany, Japan, New Zealand, Singapore, South Korea and the UK. For more information about New England Biolabs visit www.neb.com. We welcome you to our Linkedin community and we ask that you please follow our community guidelines, you can find them here: http://nebiolabs.com/community Visit us on Youtube for protocol and product videos: youtube.com/nebiolabs Follow us on Twitter: twitter.com/#!/nebiolabs